Printer Friendly

ICN AND SUBSIDIARY COMPANIES ANNOUNCE MANAGEMENT APPOINTMENTS

 ICN AND SUBSIDIARY COMPANIES ANNOUNCE MANAGEMENT APPOINTMENTS
 COSTA MESA, Calif., July 29 /PRNewswire/ -- The boards of directors of ICN Pharmaceuticals Inc. (NYSE: ICN) and its three subsidiary companies today announced a series of board and management appointments in connection with the election of Milan Panic as the new prime minister of Yugoslavia who has taken a leave of absence from the company.
 The new appointments are:
 ICN Pharmaceuticals:
 Adam Jerney, president and chief operating officer of ICN's largest subsidiary, SPI Pharmaceuticals (AMEX: SPI), was named president and chief executive officer of ICN. Roberts A. Smith, Ph.D., a member of the board of ICN and president of Viratek Inc. (NASDAQ: VIRA), ICN's pharmaceutical development company, was named vice chairman of the board.
 Elected to the ICN board were Jerney, Norman A. Barker, former chairman of the board of First Interstate Bank of California, and Birch E. Bayh Jr., former U.S. senator from Indiana and a partner in the law firm of Bayh, Connaughton, Fensterheim of Washington, D.C. Barker has been a member of the SPI board, while Bayh has been a member of the Viratek board.
 SPI Pharmaceuticals:
 Jerney, president and chief operating officer of SPI, was named to the additional post of chief executive officer. Jerney was also elected to the board of SPI.
 ICN Biomedicals (AMEX: BIM):
 Fred Andrea, vice chairman of ICN Biomedicals Inc., ICN's biotechnology research products and clinical diagnostics company, was appointed to the additional post of chief executive officer. Richard Fallis, senior vice president of operations, was named president and chief operating officer. Jerney was added to the board of directors.
 Viratek:
 Jerney was elected chief executive officer of Viratek and to its board of directors. Smith remains president of the company.
 In other moves, Barker resigned from the SPI board where he had served and Bayh resigned from the Viratek board, where he had served, in order to serve on the ICN board.
 -0- 7/29/92
 /CONTACT: Jack Sholl of ICN Pharmaceuticals, 714-545-0100, ext. 3013/
 (ICN SPI VIRA BIM) CO: ICN Pharmaceuticals Inc.; SPI Pharmaceuticals; ICN Biomedicals;
 Viratek Inc. ST: California IN: MTC SU: PER


KJ-EH -- LA011 -- 4449 07/29/92 09:15 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 29, 1992
Words:364
Previous Article:NORFOLK SOUTHERN CORPORATION REPORTS SECOND-QUARTER EARNINGS
Next Article:INDUSTRY APPLAUDS FTC ADOPTION OF 'GREEN MARKETING' GUIDELINES
Topics:


Related Articles
DR. MICHAEL SMITH, NOBEL PRIZE WINNER IN CHEMISTRY, JOINS BOARD OF ICN PHARMACEUTICALS INC.
JAMES E. WALL APPOINTED VICE PRESIDENT AND CORPORATE TREASURER
ICN PHARMACEUTICALS HIRES MANAGERS AS PART OF EXPANSION EFFORTS; THEY'LL ADDRESS DRUG DEVELOPMENT, COMMUNICATIONS AND RECRUITING
FORMER CALPERS CEO DALE HANSON JOINS BOARD OF ICN PHARMACEUTICALS
ICN PHARMACEUTICALS RECRUITS KEY MANAGERS AND ANNOUNCES PROMOTIONS; MOVE IS PART OF ICN'S WORLDWIDE EXPANSION EFFORTS
ICN Pharmaceuticals Urges Clinton to Intervene in Serbian Government Takeover of Yugoslavia Facility.
ICN's Shareholders Overwhelming Vote for CEO Milan Panic's Accomplishments and Vision for the Future; ICN Restructuring on Track.
ICN Appoints Marinko Vekovic As Senior Vice President Worldwide Sales and Marketing.
ICN International Holds First Board Meeting in Switzerland.
ICN Pharmaceuticals Announces Appointment of John I. Cooper to Senior Management Team.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters